or Try an Advanced Search...

    Technical Analysis for CYTO - Altamira Therapeutics Ltd.

    Grade Last Price % Change Price Change
    F 1.56 0.00% 0.00
    CYTO closed unchanged on Friday, May 17, 2024, on 1 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical CYTO trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    20 DMA Support Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Earnings Movers Other 0.00%
    Inside Day Range Contraction 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Crossed Above 20 DMA Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Older End-of-Day Signals for CYTO ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 1 day ago
    Possible Inside Day 1 day ago
    10 DMA Support 1 day ago
    Down 3% 1 day ago
    Fell Below 10 DMA 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CYTO Chart by TradingView
    Basic chart:

    Profile

    Altamira Therapeutics Ltd. Description

    Altamira Therapeutics is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol 'EARS.'

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Allergy Nervous System Otology

    Is CYTO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 1 Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
    Apr 24 Altamira reports publication of positive results from NASAR clinical trial with Bentrio
    Apr 24 Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
    Apr 17 Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024
    Apr 10 Altamira Therapeutics Ltd. 2023 Q4 - Results - Earnings Call Presentation
    Apr 10 Altamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call Transcript
    Apr 10 Altamira Therapeutics GAAP EPS of -CHF14.80
    Apr 10 Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
    Apr 10 Earnings Scheduled For April 10, 2024
    Apr 4 Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
    See more CYTO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 23.6
    52 Week Low 1.35
    Average Volume 1,418,852
    200-Day Moving Average 3.66
    50-Day Moving Average 1.73
    20-Day Moving Average 1.55
    10-Day Moving Average 1.52
    Average True Range 0.15
    RSI (14) 47.09
    ADX 10.95
    +DI 17.46
    -DI 14.90
    Chandelier Exit (Long, 3 ATRs) 1.32
    Chandelier Exit (Short, 3 ATRs) 1.80
    Upper Bollinger Bands 1.71
    Lower Bollinger Band 1.38
    Percent B (%b) 0.54
    BandWidth 20.91
    MACD Line -0.06
    MACD Signal Line -0.08
    MACD Histogram 0.0137
    Fundamentals Value
    Market Cap 2.46 Million
    Num Shares 1.58 Million
    EPS -453.06
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 25.01
    Price-to-Book 0.35
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.64
    Resistance 3 (R3) 1.63 1.59 1.62
    Resistance 2 (R2) 1.59 1.57 1.60 1.62
    Resistance 1 (R1) 1.58 1.56 1.59 1.59 1.61
    Pivot Point 1.54 1.54 1.55 1.55 1.54
    Support 1 (S1) 1.53 1.52 1.54 1.54 1.51
    Support 2 (S2) 1.49 1.51 1.50 1.50
    Support 3 (S3) 1.48 1.49 1.50
    Support 4 (S4) 1.49